Jazz Lung Cancer Drug Fails to Meet Main Trial Goal
Jazz Pharmaceuticals reported that its drug Zepzelca failed to improve overall survival in a late-stage study for small cell lung cancer. The company is discussing next steps with the FDA regarding the drug's current accelerated approval status.
X24 PerspectiveRelated Assets:
X24 Perspective